Boston Scientific (BSX) Non-Current Deferred Tax Liability (2009 - 2026)

Boston Scientific has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $219.0 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $219.0 million, up 38.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $219.0 million (up 38.61% YoY), and the FY2025 annual result was $220.0 million, down 0.9% from the prior year.
• Non-Current Deferred Tax Liability came in at $219.0 million for Q1 2026 at Boston Scientific, roughly flat from $220.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $278.0 million in Q3 2022 to a low of $91.0 million in Q3 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $210.0 million (2023), against an average of $188.6 million.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 130.43% in 2022 and slumped 67.27% in 2023, its largest moves.
• Boston Scientific's Non-Current Deferred Tax Liability stood at $144.0 million in 2022, then slipped by 6.94% to $134.0 million in 2023, then jumped by 65.67% to $222.0 million in 2024, then dropped by 0.9% to $220.0 million in 2025, then slipped by 0.45% to $219.0 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $219.0 million (Q1 2026), $220.0 million (Q4 2025), and $242.0 million (Q3 2025), per Business Quant data.